Iloprost Pharmamentum (Iloprost Trometamol)

Iloprost is a synthetic analogue of prostacyclin (PGI2). It binds to IP receptors on vascular smooth‑muscle cells, increasing intracellular cyclic AMP. The rise in cAMP causes relaxation of pulmonary arteries, inhibits platelet aggregation, and exerts anti‑proliferative effects on the vascular wall.

The dosing regimen for Iloprost is individualized. A qualified prescriber determines the infusion rate, concentration, and duration based on the patient’s clinical condition, response, and tolerance. No fixed dose can be stated without a medical prescription.

Safety data for Iloprost in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any potential risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare professional, considering the lack of definitive safety information.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Iloprost Pharmamentum. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Iloprost belongs to the prostacyclin analog class, offering rapid vasodilation via IP‑receptor activation. Compared with oral endothelin‑receptor antagonists or phosphodiesterase‑5 inhibitors, Iloprost provides a short‑acting, infusion‑based option that can be titrated quickly and is useful when oral agents are insufficient or not tolerated.

Iloprost should be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and avoid freezing or shaking. If a temporary temperature excursion occurs, discard the product if visual changes or cloudiness are observed.

Iloprost is administered intravenously, typically as a continuous infusion or intermittent short‑duration infusion under medical supervision. The infusion set, rate, and duration are determined by the prescribing clinician and are adjusted according to the patient’s hemodynamic response and tolerance.

Serious adverse events include severe hypotension, pulmonary edema, and significant bleeding, especially when combined with anticoagulants. Patients should be monitored closely for abrupt drops in blood pressure, respiratory distress, or signs of hemorrhage, and the infusion should be stopped immediately if these occur.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation. It should also be avoided in individuals with uncontrolled severe hypotension, active bleeding disorders, or those receiving incompatible vasodilators without careful monitoring.